Health-care companies rose slightly amid enthusiasm about drug developments.
Pfizer ticked up after the Big Pharma concern said its cancer drug Elrexfio won U.S. Food and Drug Administration accelerated approval for the treatment of adults with relapsed or refractory multiple myeloma, an incurable blood cancer.
Shares of Humacyte rallied after the biotech company said its blood-vessel repair technology was successfully used to treat injuries from combat in Ukraine.
A rally in obesity-drug maker shares continued, with a gain for Eli Lilly. Zynerba Pharmaceuticals surged after Harmony Biosciences Holdings agreed to buy the cannabinoid therapy concern for roughly $200 million.
Write to Rob Curran at rob.curran@dowjones.com
(END) Dow Jones Newswires
08-14-23 1715ET
